Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler; Hans Thorhauge Dam; R Gniadecki; Knud Kragballe; G B E Jemec; T Agner

doi:10.1111/j.1468-3083.2009.03202.x

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler, Hans Thorhauge Dam, R Gniadecki, Knud Kragballe, G B E Jemec, T Agner

Dermatology, Department of

25 Citations (Scopus)

Abstract

Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology : JEADV
Volume	24
Issue number	7
Pages (from-to)	837-9
Number of pages	3
DOIs	https://doi.org/10.1111/j.1468-3083.2009.03202.x
Publication status	Published - 1 Jul 2010

Access to Document

10.1111/j.1468-3083.2009.03202.x

Cite this

@article{84148370ed4e4d0d9d11c3bd51063794,

title = "Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases",

abstract = "Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).",

author = "K Ibler and Dam, {Hans Thorhauge} and R Gniadecki and Knud Kragballe and Jemec, {G B E} and T Agner",

year = "2010",

month = jul,

day = "1",

doi = "10.1111/j.1468-3083.2009.03202.x",

language = "English",

volume = "24",

pages = "837--9",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "7",

}

TY - JOUR

T1 - Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

AU - Ibler, K

AU - Dam, Hans Thorhauge

AU - Gniadecki, R

AU - Kragballe, Knud

AU - Jemec, G B E

AU - Agner, T

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).

AB - Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).

U2 - 10.1111/j.1468-3083.2009.03202.x

DO - 10.1111/j.1468-3083.2009.03202.x

M3 - Journal article

C2 - 19368612

VL - 24

SP - 837

EP - 839

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 7

ER -

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

Abstract

Access to Document

Fingerprint

Cite this